Apolipoprotein E4

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

1 week ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

Alzheon Investigates Subgroup Data Following Phase 3 Trial of ALZ-801 in Alzheimer’s Disease

2 weeks ago talkbio0Tagged ALZ-801, Alzheimer 's disease, Amyloid-targeting therapy, Apolipoprotein E4, Genotype, Mental deterioration, Mild cognitive disorder, Phase 3 trial, Precision Medicine, Subgroup A Nepoviruses, Valiltramiprosate

Alzheimer’s disease , ALZ-801 , Valiltramiprosate , APOE4 genotype , Mild cognitive impairment (MCI) , Amyloid-targeting therapy , Phase 3 trial results , Cognitive decline , Subgroup analysis , Precision medicine

Lexeo Therapeutics Unveils Promising Interim Data for LX1001 Gene Therapy in APOE4-Associated Alzheimer’s Disease

6 months ago talkbio0Tagged Alzheimer 's disease, Apolipoprotein E2, Apolipoprotein E4, Clinical Trials, gene therapy, Lexeo, Phase 1/2

Lexeo Therapeutics, LX1001, Gene Therapy, Alzheimer’s Disease, APOE4, APOE2, Clinical Trial, Phase 1/2